Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study.

Autor:	Velen, K, Charalambous, S, Innes, C, Churchyard, GJ, Hoffmann, CJ
Předmět:	MORTALITY risk factors CONFIDENCE intervals DNA HIV-positive persons LONGITUDINAL method SURVIVAL HIGHLY active antiretroviral therapy CASE-control method DESCRIPTIVE statistics CHRONIC hepatitis B MIXED infections DISEASE complications
Zdroj:	HIV Medicine; Oct2016, Vol. 17 Issue 9, p702-707, 6p
Abstrakt:	Objectives To assess the effect of chronic hepatitis B on survival and clinical complexity among people living with HIV following antiretroviral therapy (ART) initiation. Methods We evaluated mortality and single-drug substitutions up to 3 years from ART initiation (median follow-up 2.75 years; interquartile range 2-3 years) among patients with and without chronic hepatitis B ( CHB) enrolled in a workplace HIV care programme in South Africa. Results Mortality was increased for CHB patients with hepatitis B virus ( HBV) DNA levels > 10 000 copies/mL (adjusted hazard ratio 3.1; 95% confidence interval 1.2-8.0) compared with non- CHB patients. We did not observe a similar difference between non- CHB patients and those with CHB and HBV DNA < 10 000 copies/ mL (adjusted hazard ratio 0.70; 95% confidence interval 0.2-2.3). Single-drug substitutions occurred more frequently among coinfected patients regardless of HBV DNA level. Conclusions Our findings suggest that CHB may increase mortality and complicate ART management. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.